Back to Search
Start Over
Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone
- Publication Year :
- 2017
- Publisher :
- eScholarship, University of California, 2017.
-
Abstract
- BackgroundTherapy with evidence-based heart failure (HF) medications has been shown to be associated with lower risk of 30-day all-cause readmission in patients with HF and reduced ejection fraction (HFrEF).MethodsWe examined the association of aldosterone antagonist use with 30-day all-cause readmission in this population. Of the 2443 Medicare beneficiaries with HF and left ventricular EF ≤35% discharged home from 106 Alabama hospitals during 1998-2001, 2060 were eligible for spironolactone therapy (serum creatinine ≤2.5 for men and ≤2mg/dl for women, and serum potassium
- Subjects :
- Male
Heart Failure
Aging
Insurance Benefits
Stroke Volume
Spironolactone
Cardiorespiratory Medicine and Haematology
Medicare
Cardiovascular
Patient Readmission
United States
Treatment Outcome
Heart Disease
Cardiovascular System & Hematology
Risk Factors
Clinical Research
Alabama
Public Health and Health Services
Humans
Female
30-day all-cause readmission
Medicare beneficiaries
Mineralocorticoid Receptor Antagonists
Subjects
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.od.......325..a2d820051a363b52b27dcce4e1b02613